A1C Almanac

Main Page

The Modifiable Brain: Metabolic, Vascular, and Lifestyle Determinants of Cognitive Resilience in Aging

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:

Introduction

Cognitive decline, once considered an inevitable aspect of aging, is now recognized as a largely modifiable process influenced by lifestyle patterns and metabolic integrity. Advances in neurobiology and longevity science have revealed that the aging brain remains remarkably plastic, responding dynamically to environmental and metabolic inputs. Modifiable risk factors such as insulin resistance, chronic low-grade inflammation, and oxidative stress are now considered central mechanisms driving the early stages of cognitive deterioration.

A growing body of evidence links impaired glucose metabolism and mitochondrial dysfunction to neurodegenerative changes long before the onset of clinical symptoms. The concept of “type 3 diabetes” underscores the brain’s dependence on insulin signalling for glucose utilization and neuronal survival. Concurrently, vascular dysfunction and endothelial aging compromise cerebral perfusion, reducing nutrient and oxygen delivery to critical neuronal circuits. These metabolic derangements create a pro-inflammatory milieu that accelerates neuronal loss, synaptic instability, and cognitive decline.

Globally, the burden of dementia and related cognitive disorders continues to rise, with projections suggesting a threefold increase by 2050. Such data underscore the urgency of preventive strategies aimed at maintaining cognitive vitality across the lifespan. Within the framework of longevity medicine, brain health is increasingly viewed through a systems-based lens, one that emphasizes the interplay between metabolic, vascular, and neural networks. This perspective shifts the clinical focus from symptomatic treatment to proactive neuroprotection, highlighting the potential for lifestyle and metabolic interventions to preserve cognitive resilience well into older age.

Understanding Brain Aging and Early Cognitive Decline

Cognitive decline does not emerge suddenly; rather, it begins silently, often decades before clinically detectable memory loss or functional impairment becomes apparent. This “preclinical” phase is characterized by subtle yet progressive alterations in neuronal metabolism, synaptic integrity, and inflammatory homeostasis. During this extended latency period, pathological processes accumulate beneath the threshold of clinical detection, establishing a foundation for eventual cognitive deterioration. Biomarker studies indicate that cerebrospinal fluid abnormalities, particularly amyloid-beta deposition, may begin to diverge from normal levels up to 18 years before clinical diagnosis of Alzheimer’s disease, with tau-related markers appearing approximately 10-11 years prior to symptom onset. This extended preclinical window underscores the importance of early intervention strategies targeting modifiable metabolic and vascular risk factors [1,2,3,4].

Figure 1. A schematic illustration of multiple pathological mechanisms contributing to Alzheimer’s disease progression [1].

The mechanisms underlying early cognitive decline are multifactorial, converging on neuronal energy failure, inflammatory dysregulation, vascular compromise, and cellular quality control deficits. These pathways are interconnected, often operating synergistically to accelerate neurodegeneration. Understanding these foundational processes provides a framework for neuroprotective interventions aimed at preserving cognitive resilience across the lifespan.

Metabolic Dysfunction and Neuronal Energy Failure

The brain accounts for approximately 20% of total body energy consumption despite representing only 2% of body mass, rendering it acutely vulnerable to metabolic perturbations. Neurons rely on a continuous supply of glucose and, under conditions of metabolic stress or fasting, ketone bodies to sustain synaptic transmission, maintain ion gradients, and support plasticity. Impaired insulin signalling in the brain sometimes termed “type 3 diabetes” has emerged as a central mechanism linking metabolic dysfunction to cognitive decline [1,2,4,5].

Figure 2. Diabetes and Systemic Insulin Resistance [5].

Brain insulin resistance manifests as reduced responsiveness to insulin at multiple levels of the insulin receptor–IRS-1–PI3K–Akt signalling cascade, with the most pronounced deficits occurring downstream of the insulin receptor at IRS-1, where activation can be reduced to as low as 10% of normal levels in the hippocampal formation of individuals with Alzheimer’s disease. This insulin signalling impairment disrupts critical neuronal functions, including regulation of cerebral blood flow, synaptic plasticity, memory formation, amyloid-beta clearance, and tau phosphorylation. Positron emission tomography (PET) studies using fluorodeoxyglucose (FDG) demonstrate that individuals with insulin resistance and type 2 diabetes exhibit reduced cerebral glucose metabolism in Alzheimer’s disease-signature regions, including the parietotemporal, posterior cingulate, and precuneus cortices, even in the absence of cognitive symptoms. Importantly, genes regulating glycolysis in the brain are downregulated in correlation with cognitive decline and tau accumulation, further supporting the causal role of metabolic dysfunction in neurodegeneration [4,5,6,7].

Recent research has elucidated an age-dependent coupling mechanism between neuronal activity and mitochondrial gene transcription (E-TCmito), which is essential for maintaining neuronal energy reserves and synaptic resilience. With advancing age, this coupling becomes inefficient due to diminished activity-dependent calcium influx into mitochondria, impairing the activation of the intra-mitochondrial CaMKII-CREB signalling axis required for mitochondrial DNA transcription. Restoring this excitation-transcription coupling in aged animals has been shown to mitigate cognitive decline, positioning mitochondrial function as a viable therapeutic target [8,9].

Chronic Neuroinflammation and Microglial Dysregulation

Microglia, the resident immune cells of the central nervous system, serve as critical mediators of brain homeostasis through their roles in synaptic pruning, debris clearance, and inflammatory surveillance. However, with advancing age, microglia undergo phenotypic shifts characterized by loss of homeostatic and stress response functions, accompanied by increased translational capacity and inflammatory activation. This transition progresses through intermediate cellular states, including stress response and ribosomal upregulation phases, ultimately culminating in a chronically activated, senescent phenotype [10,11,12].

Figure 3. Microglial changes in healthy and unhealthy brain aging [10]

Senescent microglia overproduce pro-inflammatory cytokines and reactive oxygen species, creating a neurotoxic milieu that disrupts synaptic connectivity, compromises white matter integrity, and accelerates neuronal loss. Age-related iron accumulation, driven by increased expression of divalent metal-ion transporter-1 (DMT1) and decreased ferroportin expression, further exacerbates microglial dysfunction by inducing ferroptosis and contributing to cognitive decline. The resulting chronic low-grade neuroinflammation, often termed “inflammaging,” sensitizes microglia to subsequent stimuli, producing exaggerated yet ineffective responses that perpetuate neurodegeneration [11,13].

Oxidative stress is both a driver and a consequence of neuroinflammation. Reactive oxygen species generated by dysfunctional mitochondria and activated microglia induce lipid peroxidation, protein oxidation, and DNA damage, which are observed even in the early stages of mild cognitive impairment. Lipid peroxidation products, such as malondialdehyde, activate kinases involved in tau hyperphosphorylation and trigger neuronal apoptosis, creating a vicious cycle of oxidative damage and cellular dysfunction [14,15,16].

Vascular Aging and Cerebrovascular Dysfunction

The cerebrovascular endothelium serves as a dynamic interface between the systemic circulation and the brain parenchyma, regulating blood-brain barrier integrity, cerebral blood flow autoregulation, and immune surveillance. Endothelial dysfunction, characterized by impaired nitric oxide-mediated vasodilation, reduced anti-thrombotic signalling, and pro-inflammatory activation is an early and central contributor to cognitive decline. Compromised endothelial function reduces cerebral perfusion, limiting oxygen and glucose delivery to neurons and resulting in synaptic dysfunction, particularly affecting executive function and processing speed [17,18,19].

Figure 4. The Pathways of Cerebrovascular Endothelial Cell Dysfunction to Cognitive Decline [17]

Blood-brain barrier breakdown, which accelerates during middle age, allows extravasation of serum proteins such as albumin and fibrinogen into the brain parenchyma. These blood-borne molecules activate the transforming growth factor-beta (TGFβ) signalling pathway in astrocytes, triggering inflammatory cascades, glial scar formation, and neural circuit remodelling that contribute to hyperexcitability and cognitive dysfunction. Studies in aging mice demonstrate that TGFβ inhibition reverses aberrant electrocorticography activity, increases seizure threshold, and improves cognitive outcomes, suggesting that blood-brain barrier dysfunction is not merely a consequence but a driver of age-related neural pathology [20,21,22].

Cerebral small vessel disease, strongly associated with endothelial dysfunction, manifests as white matter hyperintensities, lacunar infarcts, and microbleeds on neuroimaging, and is increasingly recognized as a significant risk factor for vascular cognitive impairment and dementia. Importantly, cerebral small vessel disease pathology exhibits synergistic effects with Alzheimer’s disease, lowering the threshold for clinically significant dementia and accelerating cognitive decline [18].

Mitochondrial Decline and Cellular Quality Control Failure

Mitochondrial dysfunction is a hallmark of brain aging, characterized by reduced oxidative phosphorylation efficiency, impaired calcium handling, altered mitochondrial dynamics, and compromised quality control mechanisms. Inefficient energy production from aging mitochondria contributes to neuronal fatigue, synaptic failure, and activation of apoptotic pathways. Disrupted mitochondrial dynamics, particularly excessive fission or impaired fusion and mitophagy, induce cellular senescence and further compromise neuronal resilience [23,24,25].

Importantly, recent evidence establishes a causal link between mitochondrial dysfunction and cognitive symptoms associated with neurodegenerative diseases. Experimental restoration of mitochondrial activity in animal models of neurodegeneration improves memory deficits, reduces synaptic transmission impairment, and restores long-term potentiation, highlighting mitochondria as a mechanistic bridge between metabolic dysfunction and cognitive decline. The accumulation of amyloid-beta oligomers in mitochondrial membranes disrupts the electron transport chain, leading to excessive reactive oxygen species production, further amplifying oxidative damage and cellular dysfunction [3,26].

Synaptic Dysfunction as an Early Pathological Hallmark

Synapse loss is an early, invariant feature of Alzheimer’s disease and mild cognitive impairment, with the extent of synaptic degeneration correlating more strongly with cognitive impairment than the presence of amyloid plaques or neurofibrillary tangles. Individuals with mild Alzheimer’s disease exhibit approximately 55% fewer synapses in the hippocampal CA1 region compared to cognitively normal individuals, while those with mild cognitive impairment show an 18% reduction, positioning synaptic dysfunction as a critical structural correlate of early cognitive decline. Synaptic disruption precedes frank neuronal loss and is evident in magnetoencephalography studies, which reveal altered network synchronization and hypersynchronization patterns in mild cognitive impairment patients, suggesting compensatory responses to early disconnection [27,28,29].

Soluble forms of amyloid-beta present in the human brain correlate strongly with synaptic loss and dementia status, indicating that synaptic toxicity, rather than insoluble plaque burden may be the primary driver of early cognitive impairment. This paradigm shift underscores the importance of targeting synaptic integrity and neuronal network function in preventive interventions [29].

Evidence-Based Lifestyle Strategies for Neuroprotection

The identification of modifiable risk factors for cognitive decline has catalyzed substantial research into lifestyle interventions capable of preserving brain health across the lifespan. Mounting evidence demonstrates that metabolic optimization, nutritional sufficiency, anti-inflammatory strategies, vascular health maintenance, and cognitive-social engagement operate synergistically to protect neuronal integrity and sustain cognitive function. Unlike pharmacological approaches, these interventions target upstream pathological processes during the prolonged preclinical window, offering opportunities for primary prevention. The following sections synthesize current evidence supporting these evidence-based strategies for neuroprotection.

Optimizing Metabolic Health Through Physical Activity and Dietary Patterns

Physical activity represents one of the most robust and accessible interventions for preserving cognitive function and mitigating insulin resistance. Recent population-based analyses reveal a dose-dependent, inverted U-shaped relationship between exercise volume and cognitive performance in older adults with diabetes, with optimal benefits observed at approximately 490 MET-minutes per week for immediate recall tasks and 1,120 MET-minutes per week for processing speed assessments. Beyond these thresholds, cognitive improvements plateau, suggesting that moderate rather than excessive exercise volumes confer maximal neuroprotection [30,31].

The mechanisms underlying exercise-induced cognitive benefits are multifactorial. Moderate-intensity aerobic activity enhances insulin sensitivity both systemically and within the central nervous system, restoring brain insulin signalling that is frequently impaired in metabolic dysfunction. A groundbreaking 2025 study demonstrated that supervised exercise sessions in individuals with prediabetes significantly increased neuronal extracellular vesicles carrying insulin sensitivity proteins, particularly Akt, establishing for the first time that exercise directly impacts brain insulin signalling and improves glycemic control. This finding is critical given that brain insulin resistance, sometimes termed “type 3 diabetes” is mechanically linked to neuronal energy failure, tau hyperphosphorylation, and amyloid-beta accumulation [1,2,6,31,32,33].

Physical activity also upregulates brain-derived neurotrophic factor (BDNF), a pivotal neurotrophin supporting neurogenesis, synaptic plasticity, and neuronal survival. Aerobic exercise, even at moderate intensity (60-70% maximum heart rate), significantly elevates BDNF concentrations in the hippocampus and prefrontal cortex, regions essential for memory consolidation and executive function. A systematic review encompassing participants aged 9 to 67 years confirmed that both acute and chronic exercise regimens increase BDNF levels, with high-intensity interval training producing the most rapid and pronounced effects. Importantly, BDNF elevation correlates with improved performance on memory tests, enhanced hippocampal long-term potentiation, and reduced cognitive decline rates. Mechanistically, exercise-induced BDNF upregulation occurs through multiple pathways, including lactate-mediated induction, PGC-1α gene activation promoting irisin synthesis, and cathepsin B penetration across the blood-brain barrier [31,34,35,36].

Dietary interventions that optimize metabolic health are equally critical for neuroprotection. The Mediterranean and MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diets have emerged as evidence-based nutritional frameworks for reducing dementia risk. A 2025 meta-analysis confirmed that adherence to the Mediterranean diet is associated with an 11-30% reduction in the risk of age-related cognitive disorders, including cognitive impairment, dementia, and Alzheimer’s disease. This protective effect is primarily mediated through reduced amyloid plaque deposition rather than tau tangle formation, and persists after adjustment for physical activity, smoking, and vascular health [37,38].

The MIND diet, which uniquely emphasizes berries and green leafy vegetables rich in polyphenols and antioxidants, demonstrates similarly robust protective associations. In a prospective investigation of three cohort studies totalling 18,136 participants, the highest adherence to the MIND diet was associated with approximately 17% lower dementia risk compared to the lowest adherence. These dietary patterns support neuroprotection through multiple mechanisms: improved lipid metabolism, enhanced antioxidant capacity, reduced oxidative stress, and attenuation of systemic inflammation [37,38,39].

Time-restricted eating (TRE) and intermittent fasting represent emerging metabolic interventions with neuroprotective potential. A 2021 cross-sectional study found that individuals adhering to TRE were significantly less likely to have cognitive impairment (OR = 0.28; 95% CI: 0.07-0.90), with breakfast consumption showing independent protective effects. TRE exerts neuroprotective benefits through several pathways: enhanced synaptic plasticity and neurogenesis mediated by increased BDNF expression, improved mitochondrial respiratory activity via upregulation of PGC-1α promoting mitochondrial biogenesis, increased production of short-chain fatty acids (SCFAs) from beneficial gut microbiota such as Bifidobacterium psudolongum, which supported neuroplasticity, and restoration of circadian rhythms that reduce hypothalamic inflammation and enhance glymphatic clearance during sleep [40,41,42].

Metabolic flexibility, the capacity to dynamically switch between glucose and fat oxidation is increasingly recognized as essential for  maintaining neuronal network function, particularly during neuroinflammatory states. During moderate neuroinflammation, neurons demonstrate remarkable metabolic adaptability, increasing mitochondrial ATP production and oxygen consumption to sustain gamma oscillations even when glucose availability declines and lactate concentrations rise. This substrate-switching capability, enhanced through intermittent fasting and ketogenic interventions, protects cognitive function by preventing energy deficits during metabolic stress. Beta-hydroxybutyrate (BHB), the predominant ketone body produced during ketosis, functions not only as an alternative fuel but also as a signalling molecule that induces BDNF expression, activates Sirt1, and promotes neuronal stress resistance [42,43,44,45].

Supporting Mitochondrial Function and Nutrient Sufficiency

Mitochondrial health is foundational to cognitive resilience, and targeted nutritional interventions can enhance mitochondrial biogenesis, reduce oxidative stress, and support neurotransmitter synthesis. Omega-3 polyunsaturated fatty acids, particularly docosahexaenoic acid (DHA), are structurally integrated into neuronal membranes and play critical roles in synaptic plasticity and cellular signalling. Meta-analytic evidence indicates that omega-3 supplementation benefits specific cognitive domains, particularly in individuals with mild cognitive impairment rather than established Alzheimer’s disease or cognitively healthy populations [46,47,48,49].

A significant dose-response relationship exists: low-dose omega-3 supplementation (≤1.73 g/day) significantly reduces cognitive decline rates (SMD -0.07, 95% CI -0.13, -0.02), whereas higher doses show no significant benefit and may even be detrimental. This U-shaped dose-response pattern underscores the importance of appropriate dosing. Prospective studies demonstrate that circulating DHA levels correlate with better overall cognitive function, slower four-year cognitive decline, and superior performance on tests of psychomotor speed and executive function. Mechanistically, DHA supports mitochondrial membrane integrity, reduces lipid peroxidation, and enhances insulin signalling effects that collectively preserve neuronal energy metabolism [47,48].

B vitamins, particularly folate, vitamin B12, and vitamin B6, are essential cofactors for homocysteine metabolism, neurotransmitter synthesis, and DNA methylation. However, the relationship between B vitamin supplementation and cognitive outcomes is nuanced. Vitamin B12 intake demonstrates protective effects against cognitive decline, particularly among the oldest individuals (≥80 years), with higher intake associated with 25% slower decline rates compared to those consuming only the recommended dietary allowance. Conversely, excessively high folate intake (>400 μg/day from supplements) paradoxically accelerates cognitive decline, particularly in individuals with concurrent vitamin B12 deficiency, a phenomenon observed in the Chicago Health and Aging Project [50,51,52].

This adverse interaction likely reflects precipitation of subclinical B12 deficiency symptoms by high folic acid intake, leading to slow information processing and accelerated memory decline. The critical takeaway is that folate and B12 supplementation should be balanced, with particular caution in populations at risk for B12 malabsorption, such as older adults or those with gastric atrophy. Correcting low folate status and hyperhomocysteinemia through moderate supplementation improves memory function and processing speed, but supraphysiologic dosing should be avoided [51,52].

Magnesium is an essential cofactor for over 300 enzymatic reactions, including those critical for mitochondrial ATP production, glutamate receptor modulation, and synaptic plasticity. Within mitochondria, magnesium enables efficient glucose-to-ATP conversion; without adequate magnesium, neurons cannot produce sufficient energy for maintaining membrane potential, synthesizing neurotransmitters, or supporting structural integrity. Magnesium deficiency activates the NLRP3 inflammasome, induces neuroinflammation, increases oxidative stress via reduced superoxide dismutase activity, and disrupts synaptic transmission, all pathways contributing to cognitive decline [53,54,55].

Population-based analyses reveal that higher magnesium depletion scores correlate with lower cognitive performance, particularly in individuals with obesity (BMI >30 kg/m²), smokers, and those with dietary magnesium intake below the recommended dietary allowance. Notably, when dietary magnesium intake meets the RDA, the adverse association between magnesium depletion and cognitive decline disappears, suggesting that adequate magnesium consumption through magnesium-rich foods mitigates deficiency-related cognitive impairment. Magnesium L-threonate, a form that effectively crosses the blood-brain barrier, has been shown in animal models to increase synaptic density in the hippocampus by 15% and improve maze navigation performance, with emerging human evidence supporting cognitive benefits after 12 weeks of supplementation [53,54,55].

Coenzyme Q10 (CoQ10) functions as both an essential electron transport chain cofactor and a potent lipid-soluble antioxidant within mitochondrial membranes. Oral CoQ10 supplementation increases cerebral cortex concentrations and, critically, elevates mitochondrial CoQ10 levels in brain tissue, enhancing electron transport chain activity and preserving mitochondrial respiratory function. Animal studies demonstrate that CoQ10 administration markedly attenuates striatal lesions induced by mitochondrial toxins, reduces oxidative damage, prevents ATP depletion, and significantly extends lifespan in transgenic models of neurodegenerative disease. CoQ10 levels are reduced in Parkinson’s disease platelets and correlate with decreased complex I activity, while supplementation reduces elevated lactate concentrations in Huntington’s disease patients. These findings position CoQ10 as a viable adjunctive strategy for preserving mitochondrial function and preventing neurodegeneration [56,57].

Intermittent fasting and mild ketosis, beyond their metabolic benefits, powerfully stimulate autophagy and mitophagy—cellular quality control mechanisms that remove damaged mitochondria and protein aggregates. Ketogenic diets activate autophagic pathways through multiple mechanisms: downregulation of mTORC1, activation of AMP-activated kinase and Sirt1, elevation of hypoxia-inducible factor-1α (HIF-1α), and increased NAD+ availability. In animal models, ketogenic diets increase hippocampal markers of autophagy (Atg5, Beclin-1, LC3-II/LC3-I ratio) while decreasing the autophagy substrate p62, indicating enhanced autophagic flux. This upregulation of neuronal autophagy facilitates elimination of damaged mitochondria that overproduce superoxide and clearance of neurotoxic protein aggregates, thereby preventing neurodegenerative cascades. Importantly, the magnitude of these effects varies by brain region, the hippocampus exhibits more robust responses than the frontal cortex and is influenced by the type of dietary fat, with plant-based fats exerting more profound effects [40,42,44,58,59,60,61].

Reducing Neuroinflammation Through Diet, Stress Management, and Sleep Optimization

Dietary polyphenols represent a diverse class of plant-derived compounds with potent anti-inflammatory and neuroprotective properties. Curcumin, a polyphenolic compound derived from turmeric, has emerged as a particularly well-studied neuroinflammatory modulator. Curcumin effectively inhibits the NF-κB pathway. A master regulator of inflammation by preventing IκBα phosphorylation and degradation, thereby blocking NF-κB p65 nuclear translocation and subsequent pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). In Alzheimer’s disease models, curcumin administration downregulates hippocampal expression of HMGB1, RAGE, TLR4, and NF-κB, improving cognitive function by suppressing this inflammatory signalling cascade [62,63].

Beyond NF-κB inhibition, curcumin suppresses microglial NLRP3 inflammasome activation, reduces malondialdehyde and oxidative stress markers, enhances BDNF-ERK signalling to mitigate cognitive deficits, and facilitates amyloid-beta clearance from brain to peripheral circulation. Importantly, curcumin demonstrates multifaceted molecular functions by activating PPARγ, which further suppresses neuroinflammation and enhances neuronal function; this benefit is abolished when PPARγ is blocked or silenced. In models of Parkinson’s disease, curcumin prevents α-synuclein aggregation and mitigates LPS-induced dopaminergic neurodegeneration through NF-κB inhibition. A 2024 meta-analysis confirmed that polyphenol supplementation significantly reduces inflammatory biomarkers (CRP, IL-6) in human randomized controlled trials, with corresponding improvements in cognitive performance [62,63,64].

Other polyphenolic compounds, including resveratrol, pterostilbene, green tea catechins, and berry anthocyanins exert similar anti-inflammatory effects by downregulating NF-κB, reducing microglial activation, and enhancing antioxidant defenses. These compounds cross the blood-brain barrier, accumulate in vulnerable brain regions, and provide direct neuroprotection against oxidative damage and excitotoxicity [62,65].

Stress management through mindfulness meditation, yoga, and relaxation techniques reduces cortisol-driven neuroinflammation and preserves cognitive function. Chronic elevation of cortisol, a glucocorticoid hormone released during prolonged stress contributes to hippocampal atrophy, impairs neurogenesis, and sensitizes microglia to inflammatory stimuli. Mindfulness meditation training has been shown to significantly decrease serum cortisol levels and perceived stress in multiple randomized controlled trials. A 2016 study from the Shamatha Project demonstrated a direct inverse correlation between mindfulness scores and resting cortisol levels: individuals with higher mindfulness (greater focus on immediate sensory experience) exhibited lower cortisol concentrations, and those whose mindfulness scores increased after a meditation retreat showed corresponding cortisol reductions [66,67].

Systematic reviews of 45 randomized controlled trials identified strong evidence that mindfulness meditation reduces serum cortisol and C-reactive protein (CRP), a systemic inflammatory marker. The hypothesized mechanism involves buffering of stress reactivity, resulting in decreased hypothalamic-pituitary-adrenal axis activation and reduced pro-inflammatory cytokine release. While initial meditation training in novices may transiently increase cortisol responses to acute stressors (possibly reflecting more proactive coping strategies), sustained practice consistently reduces basal cortisol and inflammatory tone [67,68].

Sleep quality and duration are critical modulators of neuroinflammation and cognitive health. Sleep deprivation induces a pro-inflammatory state characterized by microglial activation via the NF-κB pathway, astrocyte dysfunction, increased IL-6 and other pro-inflammatory cytokine release, and elevated oxidative stress. Even 24-48 hours of total sleep deprivation significantly impairs performance across most cognitive domains, particularly vigilance, complex attention, and working memory with lesser but measurable effects on processing speed [69,70,71,72].

Chronic sleep disturbance specifically increases IL-6 levels and induces microglial activation in the hippocampus, impairing hippocampus-dependent learning and memory. Neuroinflammation triggered by sleep loss also disrupts synaptic plasticity, impairs neurotransmitter balance, and interferes with glymphatic clearance, the brain’s waste removal system that operates predominantly during sleep leading to accumulation of beta-amyloid and other neurotoxic metabolites. Prolonged sleep deprivation dysregulates the hypothalamic-pituitary-adrenal axis, elevating systemic cortisol and CRP levels and creating a vicious cycle wherein neuroinflammation and neurotransmitter imbalance reinforce one another, accelerating cognitive deterioration [66,69,71,72].

Single-cell transcriptomic analyses in sleep-deprived mice reveal activation of inflammatory, oxidative stress, and integrated stress response pathways in GABAergic neurons, with enrichment of pathways associated with Alzheimer’s disease, Huntington’s disease, and neurodegeneration. Population-based studies confirm that severe short sleep (<6 hours) correlates with lower cognitive test scores and that higher systemic immune-inflammation index (SII) levels independently predict worse cognitive performance. Collectively, these findings position adequate sleep (7-9 hours for most adults) as a foundational pillar of neuroprotection, with sleep optimization potentially mitigating neuroinflammatory cascades and preserving cognitive resilience [69,70,71,73].

Enhancing Cerebrovascular Function and Maintaining Vascular Health

Cerebrovascular health is inextricably linked to cognitive function, and interventions that optimize blood pressure, endothelial function, and cerebral perfusion are critical for preventing vascular cognitive impairment. Hypertension disrupts the structural and functional integrity of the cerebral vasculature through multiple mechanisms: endothelial dysfunction characterized by impaired nitric oxide-mediated vasodilation, blood-brain barrier breakdown, neurovascular uncoupling (impaired matching of blood flow to neuronal metabolic demand), and microvascular rarefaction [74,75,76].

Cross-sectional epidemiologic studies using representative samples of the U.S. population demonstrate that elevated blood pressure and poorly controlled hypertension are associated with lower cognitive function, particularly on tests of perceptuo-motor speed and manual dexterity, independent of age, gender, education, and stroke history. Longitudinal evidence indicates that maintenance of blood pressure in the normal range attenuates hypertension-related cognitive decline, whereas excessively aggressive blood pressure reduction, especially in the elderly can cause cerebral hypoperfusion and paradoxical cognitive loss. The Heart Outcomes Prevention Evaluation study demonstrated that optimal blood pressure control enhances cognitive function in older adults, suggesting a therapeutic window wherein moderate reduction preserves perfusion while preventing vascular damage [74,75].

Hypertension-induced cerebrovascular dysfunction manifests as impaired functional hyperemia (reduced regional blood flow increases during cognitive tasks), diminished autoregulatory capacity, and increased susceptibility to vascular insufficiency. In untreated hypertensives, higher baseline blood pressure correlates with blunted cerebral blood flow responses to cognitive tasks and visual stimuli. Chronic hypertension also promotes cerebral small vessel disease, characterized by white matter hyperintensities, lacunar infarcts, and microbleeds which synergistically interacts with Alzheimer’s pathology to lower the threshold for clinically significant dementia [18,75,76].

Blood pressure variability (BPV), both short-term and long-term, independently predicts cognitive outcomes. Meta-analyses combining 53 studies found that worse cognitive performance is associated with medium- and long-term BPV, while very short-term low BPV (impaired ability to adjust perfusion with postural changes) also elevates risk of poor cognitive outcomes. These findings emphasize that blood pressure stability, not just absolute values, is critical for cognitive health [75].

Aerobic exercise serves dual roles in vascular neuroprotection: it reduces blood pressure, improves endothelial function, and directly enhances cerebrovascular health through upregulation of BDNF and vascular endothelial growth factor (VEGF). Endothelial dysfunction in peripheral arteries, indicative of systemic vascular compromise s associated with brain microhemorrhages and white matter lesions, both of which contribute to cognitive decline. Exercise-induced improvements in endothelial nitric oxide availability, reduced arterial stiffness, and enhanced cerebral autoregulation collectively optimize cerebral perfusion and protect against vascular cognitive impairment [31,34,35,74,75,76].

Engaging Cognitive and Social Networks to Build Cognitive Reserve

Cognitive reserve, defined as the brain’s resilience to pathological damage through recruitment of alternative neural networks and compensatory mechanisms, is a modifiable determinant of dementia risk. Regular cognitive engagement including learning new skills, acquiring languages, playing musical instruments, and participating in intellectually demanding activities strengthens neuronal connections, enhances synaptic density, and builds reserve capacity that buffers against age-related decline [77,78,79].

A 2025 randomized controlled trial demonstrated that combining cognitive training (the StrongerMemory program involving reading, writing, and math exercises) with weekly social engagement produced significantly greater improvements in cognitive function, behavioral outcomes, and emotional well-being compared to cognitive training alone in older adults with subjective cognitive decline. Social engagement operates through multiple protective mechanisms: facilitating social learning and cognitive stimulation, promoting emotional regulation and stress buffering, encouraging positive health behaviors, and providing opportunities for meaningful social interaction, all of which contribute to cognitive reserve [77,78,79].

Longitudinal cohort studies and meta-analyses consistently show that higher levels of social connection and more frequent participation in social activities correlate with superior cognitive function and lower dementia risk. The Alzheimer’s Association notes that among older individuals with genetic risk for dementia, rates of dementia were significantly lower among those who frequently engaged in social activities, with variety and frequency of engagement both playing protective roles in individuals with early-stage memory loss or mild cognitive impairment [77,78,79].

Life-course analyses reveal that cognitive reserve accumulation at different life stages contributes differentially to dementia risk reduction. Education in early life, occupation and social network contact in midlife, and cognitive activity and social connection in late life all exert significant protective effects, with early-life and late-life proxies demonstrating the most pronounced impacts. Among late-life cognitive reserve proxies, social connection emerged as potentially the most effective approach for reducing dementia risk, exhibiting protective associations even stronger than cognitive activity alone [78].

Mechanistically, social engagement enhances cognitive reserve by maintaining and expanding neuronal networks, promoting neuroplasticity, reducing chronic stress and inflammation, and supporting purpose-driven living, all factors that preserve cognitive vitality and delay the clinical expression of neurodegenerative pathology. These findings underscore the importance of integrating social and cognitive interventions into comprehensive dementia prevention strategies, particularly for individuals experiencing subjective cognitive decline or early mild cognitive impairment [77,78,79].

Emerging Frontiers in Brain Longevity Medicine

Emerging interventions are beginning to complement lifestyle medicine by targeting upstream drivers of brain aging, but most remain in early translational stages and should be interpreted cautiously.

Senolytics and Cellular Senescence

Cellular senescence contributes to brain aging through the accumulation of senescent cells that secrete a senescence‑associated secretory phenotype (SASP), rich in pro‑inflammatory cytokines, chemokines, and proteases that propagate neuroinflammation and synaptic dysfunction. In mouse models, genetic or pharmacologic clearance of senescent cells (using senolytics such as dasatinib plus quercetin or BCL‑2 family inhibitors) reduces microglial activation, attenuates age‑related brain inflammation, and improves learning and memory performance. A first‑in‑human pilot trial of senolytics in older adults with early Alzheimer’s pathology reported that intermittent dosing was feasible and biologically active, but effects on cognition and mobility were modest and variable, underscoring the need for larger, longer studies. Importantly, recent work in aging female rats showed no cognitive benefit from chronic senolytic treatment and suggested sex‑specific responses related to estradiol loss and immune differences, highlighting that senolytic strategies may require sex‑ and context‑specific tailoring and carry potential off‑target risks [80,81,82,83,84].

NAD+ Boosters and Neuronal Energetics

Age‑related declines in nicotinamide adenine dinucleotide (NAD⁺) impair mitochondrial function, DNA repair, and sirtuin signaling, all of which are central to neuronal resilience and synaptic plasticity. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are orally bioavailable NAD⁺ precursors that increase circulating and tissue NAD⁺ levels and improve cognitive outcomes in several rodent models of neurodegeneration. In a randomized, placebo‑controlled pilot study of older adults with mild cognitive impairment, 1 g/day NR for 10 weeks significantly increased blood NAD⁺ concentrations and was well tolerated but did not produce measurable improvement on the Montreal Cognitive Assessment or secondary neuropsychological endpoints over the short follow‑up period. Preclinical work suggests that NR supplementation can partially “rejuvenate” aged microglia by reversing disease‑associated transcriptional signatures and restoring more youthful metabolic profiles, which may, in turn, mitigate age‑related cognitive decline; however, definitive human evidence for cognitive benefit is still lacking. Overall, NAD⁺ boosters are promising as metabolic support for the aging brain, but they should currently be viewed as experimental adjuncts pending larger, longer-duration trials with clinical endpoints [85,86].

Gut-Brain Axis Modulation

The gut microbiota communicates bidirectionally with the central nervous system via neural, immune, endocrine, and metabolic pathways, and dysbiosis has been linked to neuroinflammation, altered neurotransmission, and cognitive deficits. Probiotics, typically strains of Lactobacillus and Bifidobacterium can restore microbial balance, lower intestinal pH, reduce gut permeability, and decrease systemic inflammatory signalling, thereby indirectly modulating brain function. Experimental and early clinical data indicate that specific probiotic formulations increase brain‑derived neurotrophic factor (BDNF), influence microglial maturation and astrocyte polarization, and alter hippocampal expression of serotonin receptors (5‑HT1A and 5‑HT2C), changes that are associated with improved learning, memory, and emotional regulation. Reviews integrating animal and human studies conclude that probiotic and prebiotic interventions can modestly enhance cognitive performance and may be useful in preventing or attenuating cognitive decline, but strain specificity, dosing, and long‑term safety remain important unanswered questions. In parallel, fiber‑rich diets that support short‑chain fatty acid–producing microbes appear to reinforce gut barrier integrity and temper microglial activation, offering a nutritional route to gut–brain axis modulation within standard dietary frameworks [87,88].

Digital Biomarkers and AI-Driven Early Detection

Traditional neuropsychological tests often lack sensitivity to the subtle, multidomain changes that characterize the preclinical phase of neurodegenerative disease. Digital biomarkers derived from speech, language, keystroke dynamics, motor patterns, wearable sensors, and virtual reality (VR) tasks capture high-frequency, ecologically valid data that can reveal fine‑grained alterations in memory, executive function, and processing speed years before overt impairment. Recent systematic reviews highlight that AI and machine‑learning models trained on multimodal digital data (conversational language, reaction times, navigation paths, and neuroimaging features) can discriminate preclinical Alzheimer’s disease from healthy aging with higher accuracy than single traditional cognitive measures, particularly when focused on verbal episodic memory and executive function. VR‑based assessments allow immersive, real‑world–like evaluation of navigation, shopping, and instrumental activities of daily living, and their integration with AI analytics offers the potential for highly personalized, longitudinal monitoring of cognitive trajectories in both clinical and home environments. As regulatory frameworks and validation studies progress, these digital tools are poised to shift brain longevity medicine from episodic, clinic‑based testing toward continuous, preventive neurology that detects and tracks cognitive decline at its earliest, most modifiable stages [89].

Conclusion

Protecting the brain from early cognitive decline requires a comprehensive strategy that addresses the metabolic, vascular, and inflammatory determinants of neuronal health. Rather than emerging abruptly, cognitive deterioration reflects the cumulative impact of insulin resistance, cerebrovascular dysfunction, and chronic low-grade neuroinflammation acting over decades. Interventions that preserve insulin sensitivity, maintain endothelial function, and modulate inflammatory tone therefore represent central pillars of brain-protective care across the lifespan.

Within this framework, lifestyle-based interventions remain the most accessible, scalable, and evidence-supported tools for preserving cognition and extending health span. Nutritional patterns that prioritize whole, minimally processed foods; regular aerobic and resistance exercise; restorative sleep; and structured cognitive and social engagement collectively enhance neuroplasticity, support mitochondrial function, and build cognitive reserve. These approaches not only delay the onset of clinical symptoms but also modify upstream biological pathways that underlie neurodegenerative disease.

As longevity medicine continues to evolve, the integration of metabolic, nutritional, vascular, and neurobiological insights will progressively redefine what it means to age with mental clarity and functional independence. Emerging modalities, such as senolytics strategies, NAD⁺ augmentation, gut–brain axis modulation, and digital biomarkers are likely to complement, rather than replace, foundational lifestyle measures. A future-oriented brain longevity paradigm will thus emphasize early identification of risk, personalized intervention, and continuous monitoring, with the goal of sustaining cognitive vitality well into advanced age.

Reference

  1. Fereshteh Atabi, Mahdi Moassesfar, Nakhaie T, Mobina Bagherian, Niloufar Hosseinpour, Hashemi M. A systematic review on type 3 diabetes: bridging the gap between metabolic dysfunction and Alzheimer’s disease. Diabetology & Metabolic Syndrome. 2025 Aug 27;17(1).
  2. Verma A, Sharma M, Alam O, Anwer T. Type 3 Diabetes: A Molecular Link Between Cerebral Insulin Resistance and Neurodegeneration via AGE–RAGE Signaling. European Journal of Neuroscience. 2025 Dec 29;63(1).
  3. Stavroula Ioannidou, Tsolaki M, Argyrios Ginoudis, Androniki Tamvakis, Anthoula Tsolaki, Makedou K, et al. Oxidative Stress Biomarkers as Preclinical Markers of Mild Cognitive Impairment: The Impact of Age and Sex. Journal of Personalized Medicine [Internet]. 2025 Apr 26;15(5):171–1. Available from: https://www.mdpi.com/2075-4426/15/5/171
  4. Moawad H. Should We Think of Alzheimer’s Disease as Type 3 Diabetes? [Internet]. Medscape. 2025 [cited 2026 Feb 1]. Available from: https://www.medscape.com/viewarticle/should-we-think-alzheimers-disease-type-3-diabetes-2025a1000l05
  5. Soltani S, Dolatshahi M, Soltani S, Khazaei K, Rahmani M, Raji CA. Relationships Between Brain Glucose Metabolism Patterns and Impaired Glycemic Status: A Systematic Review of FDG‐PET Studies With a Focus on Alzheimer’s Disease. Human Brain Mapping. 2025 Mar;46(4).
  6. Talbot K. Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs. Neurodegenerative Disease Management. 2014 Feb;4(1):31–40.
  7. Kellar D, Craft S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. The Lancet Neurology [Internet]. 2020 Sep 1;19(9):758–66. Available from: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30231-3/fulltext#:~:text=Insulin also has a role
  8. Chen H, Cao L, Liu S, Yuan K. A new route for mitigating age-related cognitive decline. Ageing and Neurodegenerative Diseases [Internet]. 2025 Nov 25 [cited 2026 Feb 1];5(4). Available from: https://www.oaepublish.com/articles/and.2025.16
  9. News Medical. News-Medical [Internet]. News-Medical. 2025 [cited 2026 Feb 1]. Available from: https://www.news-medical.net/news/20250811/Study-establishes-a-causal-link-between-mitochondrial-dysfunction-and-neurodegenerative-diseases.aspx
  10. Fan H, Zhang M, Wen J, Wang S, Yuan M, Sun H, et al. Microglia in brain aging: An overview of recent basic science and clinical research developments. Journal of Biomedical Research [Internet]. 2023 Jun 8;38(2):122–2. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11001587/
  11. Duggan MR, Parikh V. Microglia and modifiable life factors: Potential contributions to cognitive resilience in aging. Behavioural Brain Research. 2021 May;405:113207.
  12. Shea JM, Villeda SA. Microglia aging in the hippocampus advances through intermediate states that drive inflammatory activation and cognitive decline. bioRxiv (Cold Spring Harbor Laboratory) [Internet]. 2024 Jun 14; Available from: https://elifesciences.org/articles/97671/peer-reviews
  13. Liu K, Fan D, Wu H, Hu X, He Q, Wu X, et al. Senescent Microglia Mediate Neuroinflammation‐Induced Cognitive Dysfunction by Selective Elimination of Excitatory Synapses in the Hippocampal CA1. Aging Cell. 2025 Jul 7;24(9).
  14. Stavroula Ioannidou, Tsolaki M, Argyrios Ginoudis, Androniki Tamvakis, Anthoula Tsolaki, Makedou K, et al. Oxidative Stress Biomarkers as Preclinical Markers of Mild Cognitive Impairment: The Impact of Age and Sex. Journal of Personalized Medicine [Internet]. 2025 Apr 26;15(5):171–1. Available from: https://www.mdpi.com/2075-4426/15/5/171
  15. Lv H, Liu Y, Yang X, Xu X, Zhou J, Yu W. Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment. Journal of Stroke and Cerebrovascular Diseases [Internet]. 2025 Oct 17;34(12):108475. Available from: https://www.sciencedirect.com/science/article/pii/S1052305725002526
  16. Guo X, Sun G, Zhou T, Wang Y, Xu X, Shi X, et al. LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy. Acta Pharmacologica Sinica [Internet]. 2017 Jun 26;38(8):1104–19. Available from: https://www.nature.com/articles/aps2016128
  17. Wang F, Cao Y, Ma L, Pei H, Rausch WD, Li H. Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia. Frontiers in Aging Neuroscience. 2018 Nov 16;10.
  18. Sun K, Liu H. Emerging biomarkers and frontier therapies: unveiling the role of endothelial dysfunction in cerebral small vessel disease. Frontiers in Neurology. 2025 Jul 11;16:1615883–3.
  19. Negri S, Reyff Z, Troyano-Rodriguez E, Milan M, Ihuoma J, Tavakol S, et al. Endothelial Colony-Forming Cells (ECFCs) in cerebrovascular aging: Focus on the pathogenesis of Vascular Cognitive Impairment and Dementia (VCID), and treatment prospects. Ageing Research Reviews [Internet]. 2025 Jan 28;104:102672. Available from: http
  20. Senatorov VV, Friedman AR, Milikovsky DZ, Ofer J, Saar-Ashkenazy R, Charbash A, et al. Blood-brain barrier dysfunction in aging induces hyperactivation of TGFβ signaling and chronic yet reversible neural dysfunction. Science Translational Medicine. 2019 Dec 4;11(521).
  21. Preininger MK, Dasha Zaytseva, Jessica May Lin, Kaufer D. Blood–brain barrier dysfunction promotes astrocyte senescence through albumin‐induced TGFβ signaling activation. Aging Cell. 2023 Jan 5;22(2).
  22. Hussain B, Fang C, Chang J. Blood–Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia. Frontiers in Neuroscience. 2021 Aug 19;15.
  23. Adlimoghaddam A. Mitochondrial Dysfunction in Aging and Age-related Disorders. PubMed. 2025 Jul 31;16(5):2495–7.
  24. Jia L, Wei Z, Jinyuan Luoqian, Wang X, Huang C. Mitochondrial Dysfunction in Aging: Future Therapies and Precision Medicine Approaches. MedComm – Future Medicine. 2025 Jul 17;4(3).
  25. Hruby AJ, Higuchi-Sanabria R. Mitochondrial dysfunction in cellular senescence: a bridge to neurodegenerative disease. npj Aging [Internet]. 2025 Dec 16 [cited 2026 Feb 1];11(1). Available from: https://www.nature.com/articles/s41514-025-00291-4
  26. News Medical. News-Medical [Internet]. News-Medical. 2025. Available from: https://www.news-medical.net/news/20250811/Study-establishes-a-causal-link-between-mitochondrial-dysfunction-and-neurodegenerative-diseases.aspx
  27. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007 Apr 30;68(18):1501–8.
  28. Maestú F, José Roda Peña, Garcés P, Santiago Álvarez González, Bajo R, Anto Bagic, et al. A multicenter study of the early detection of synaptic dysfunction in Mild Cognitive Impairment using Magnetoencephalography-derived functional connectivity. NeuroImage: Clinical. 2015 Jan 1;9:103–9.
  29. Shankar GM, Walsh DM. Alzheimer’s disease: synaptic dysfunction and Aβ. Molecular Neurodegeneration. 2009;4(1):48.
  30. Wang Y, Liu D, Wang H, Wang M, Ruan W, Han Y, et al. The role of physical activity in preventing cognitive decline among U.S. older adults with diabetes and prediabetes: a cross-sectional study. Frontiers in Public Health. 2025 Jun 24;13.
  31. Ren J, Li H, Liufu L, Yang Y, Long D, Liu H, et al. Threshold effects of physical activity and cognitive function among older adults with diabetes mellitus in NHANES 2011–2014. Aging Clinical and Experimental Research [Internet]. 2025 Dec 29 [cited 2026 Feb 1];38(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12748289/
  32. zurowska. Exercise May Boost Brain Function by Enhancing Insulin Sensitivity [Internet]. European Medical Journal. EMJ; 2025 [cited 2026 Feb 1]. Available from: https://www.emjreviews.com/diabetes/news/exercise-may-boost-brain-function-by-enhancing-insulin-sensitivity/
  33. MD T. News-Medical [Internet]. News-Medical. 2025. Available from: https://www.news-medical.net/news/20250128/Exercise-improves-brain-insulin-sensitivity-and-lowers-dementia-risk-in-older-adults-with-prediabetes.aspx
  34. Grimanesa S, Leon-Rojas JE. The Effect of Aerobic Exercise in Neuroplasticity, Learning, and Cognition: A Systematic Review. Curēus. 2024 Feb 11;16(2).
  35. Kong L, Miu L, Yao W, Shi Z. Effect of Regular Aerobic Exercise on Cognitive Function, Depression Level and Regulative Role of Neurotrophic Factor: A Prospective Cohort Study in the Young and the Middle-Aged Sample. Risk Management and Healthcare Policy [Internet]. 2024 Apr 12;17:935–43. Available from: https://www.dovepress.com/effect-of-regular-aerobic-exercise-on-cognitive-function-depression-le-peer-reviewed-fulltext-article-RMHP
  36. Tutakhail A, Diarra F, Coudoré F, Mendez-David I, David DJ. Harnessing exercise for brain health: BDNF, neuroplasticity & well-being. L’Encéphale [Internet]. 2025 Nov 7; Available from: https://www.sciencedirect.com/science/article/abs/pii/S001370062500171X
  37. MIND and Mediterranean diets linked to fewer signs of Alzheimer’s brain pathology [Internet]. National Institute on Aging. 2023. Available from: https://www.nia.nih.gov/news/mind-and-mediterranean-diets-linked-fewer-signs-alzheimers-brain-pathology
  38. Fekete M, Varga P, Zoltan Ungvari, Fekete JT, Buda A, Ágnes Szappanos, et al. The role of the Mediterranean diet in reducing the risk of cognitive impairement, dementia, and Alzheimer’s disease: a meta-analysis. GeroScience. 2025 Jan 11;
  39. Chen H, Dhana K, Huang Y, Huang L, Tao Y, Liu X, et al. Association of the Mediterranean Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet With the Risk of Dementia. JAMA Psychiatry. 2023 May 3;80(6).
  40. Currenti W, Godos J, Castellano S, Caruso G, Ferri R, Caraci F, et al. Association between Time Restricted Feeding and Cognitive Status in Older Italian Adults. Nutrients. 2021 Jan 9;13(1):191.
  41. King MW, Chen Y, Musiek ES. Time-restricted feeding and Alzheimer’s disease: you are when you eat. Trends in molecular medicine [Internet]. 2023 Dec;29(12):974–5. Available from: https://pubmed.ncbi.nlm.nih.gov/37872024/
  42. Hein ZM, Arbain MFF, Kumar S, Mehat MZ, Hamid HA, Che Ramli MD, et al. Intermittent Fasting as a Neuroprotective Strategy: Gut–Brain Axis Modulation and Metabolic Reprogramming in Neurodegenerative Disorders. Nutrients. 2025 Jul 9;17(14):2266.
  43. Chausse B, Nikolai Malorny, Lewen A, Gernot Poschet, Berndt N, Kann O. Metabolic flexibility ensures proper neuronal network function in moderate neuroinflammation. Scientific Reports. 2024 Jun 22;14(1).
  44. Gough SM, Casella A, Ortega KJ, Hackam AS. Neuroprotection by the Ketogenic Diet: Evidence and Controversies. Frontiers in Nutrition. 2021 Nov 23;8.
  45. Mattson MP, Moehl K, Ghena N, Schmaedick M, Cheng A. Intermittent metabolic switching, neuroplasticity and brain health. Nature Reviews Neuroscience [Internet]. 2018 Jan 11;19(2):80–0. Available from: https://www.nature.com/articles/nrn.2017.156
  46. Shahinfar H, Yazdian Z, Avini NA, Torabinasab K, Shab-Bidar S. A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function. Scientific Reports. 2025 Aug 20;15(1).
  47. Muldoon MF, Ryan CM, Yao JK, Conklin SM, Manuck SB. Long-Chain Omega-3 Fatty Acids and Optimization of Cognitive Performance. Military Medicine. 2014 Nov;179(11S):95–105.
  48. Naderali E, Naderali MM, Abubakari AR. Omega-3 fatty acid supplementation and cognitive function: are smaller dosages more beneficial? International Journal of General Medicine. 2014 Sep;463.
  49. Mazereeuw G, Lanctôt KL, Chau SA, Swardfager W, Herrmann N. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiology of Aging [Internet]. 2012 Jul;33(7):1482.e17–29. Available from: https://www.sciencedirect.com/science/article/abs/pii/S019745801100546X?via%3Dihub
  50. Morris MC, Evans DA, Bienias JL, Tangney CC, Hebert LE, Scherr PA, et al. Dietary Folate and Vitamin B12 Intake and Cognitive Decline Among Community-Dwelling Older Persons. Archives of Neurology. 2005 Apr 1;62(4):641.
  51. Morris MS. The Role of B Vitamins in Preventing and Treating Cognitive Impairment and Decline. Advances in Nutrition. 2012 Nov 1;3(6):801–12.
  52. Agnew-Blais JC, Wassertheil-Smoller S, Kang JH, Hogan PE, Coker LH, Snetselaar LG, et al. Folate, Vitamin B-6, and Vitamin B-12 Intake and Mild Cognitive Impairment and Probable Dementia in the Women’s Health Initiative Memory Study. Journal of the Academy of Nutrition and Dietetics. 2015 Feb;115(2):231–41.
  53. Li G, Zhou N, Wang H, Wang C. Association of magnesium depletion score with cognitive function in older adults: An analysis of US National Health and Nutrition Examination Survey (NHANES) 2011 to 2014. Medicine [Internet]. 2025 Oct 17;104(42):e45231. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12537121/
  54. Patel V, Akimbekov NS, Grant WB, Dean C, Fang X, Razzaque MS. Neuroprotective effects of magnesium: implications for neuroinflammation and cognitive decline. Frontiers in Endocrinology. 2024 Sep 25;15.
  55. Magnesium’s Role in Cognitive Performance and Memory (Full Article) [Internet]. MindSpaceX. 2025 [cited 2026 Feb 1]. Available from: https://www.mindspacex.com/post/magnesium-s-role-in-cognitive-performance-and-memory-full-article
  56. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proceedings of the National Academy of Sciences. 1998 Jul 21;95(15):8892–7.
  57. Mancuso M, Orsucci D, Calsolaro V, Choub A, Siciliano G. Coenzyme Q10 and Neurological Diseases. Pharmaceuticals [Internet]. 2009 Dec [cited 2026 Feb 1];2(3):134. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3978538/
  58. McCarty MF, DiNicolantonio JJ, O’Keefe JH. Ketosis may promote brain macroautophagy by activating Sirt1 and hypoxia-inducible factor-1. Medical Hypotheses. 2015 Nov;85(5):631–9.
  59. Monda A, Ester M, Messina A, Maio GD, Monda V, Moscatelli F, et al. Exploring the ketogenic diet’s potential in reducing neuroinflammation and modulating immune responses. Frontiers in Immunology. 2024 Aug 12;15.
  60. Wang BH, Hou Q, Lu YQ, Jia MM, Qiu T, Wang XH, et al. Ketogenic diet attenuates neuronal injury via autophagy and mitochondrial pathways in pentylenetetrazol-kindled seizures. Brain Research. 2017 Oct 19;1678:106–15.
  61. Liśkiewicz D, Liśkiewicz A, Nowacka-Chmielewska MM, Grabowski M, Pondel N, Grabowska K, et al. Differential Response of Hippocampal and Cerebrocortical Autophagy and Ketone Body Metabolism to the Ketogenic Diet. Frontiers in Cellular Neuroscience. 2021 Aug 11;15.
  62. Abdullah Al Mamun, Shao C, Geng P, Wang S, Xiao J. Polyphenols Targeting NF-κB Pathway in Neurological Disorders: What We Know So Far? International journal of biological sciences [Internet]. 2024 Jan 1;20(4):1332–55. Available from: https://doi.org/10.7150%2Fijbs.90982
  63. Zhou B, Hu B. Anti-inflammatory effect of curcumin on neurological disorders: a narrative review. Frontiers in Pharmacology. 2025 Oct 8;16:1658115–5.
  64. Chusana Mekhora, Lamport DJ, Jeremy P.E. Spencer. Effect of polyphenols on inflammation related to cognitive function: a systematic review and meta-analysis of human randomized controlled trials. Nutrition and Healthy Aging [Internet]. 2024 Sep 5;9(1):113–31. Available from: https://www.researchgate.net/publication/383843712_Effect_of_polyphenols_on_inflammation_related_to_cognitive_function_a_systematic_review_and_meta-analysis_of_human_randomized_controlled_trials
  65. Jalouli M, Rahman MA, Biswas P, Rahman H, Harrath AH, Lee IS, et al. Targeting natural antioxidant polyphenols to protect neuroinflammation and neurodegenerative diseases: a comprehensive review. Frontiers in Pharmacology. 2025 Jan 24;16.
  66. Younas A, Sarath Vayolipoyil, Shaheera Raghib, Bano S, Abali Wandala, Khan AA, et al. The Impact of Sleep Deprivation on Brain Fog, Cognitive Decline, and Cardiovascular Risk in Young Adults. Cureus. 2025 May 8;
  67. Alhawatmeh HN, Rababa M, Alfaqih M, Albataineh R, Hweidi I, Abu Awwad A. The Benefits of Mindfulness Meditation on Trait Mindfulness, Perceived Stress, Cortisol, and C-Reactive Protein in Nursing Students: A Randomized Controlled Trial. Advances in Medical Education and Practice. 2022 Jan;Volume 13:47–58.
  68. Creswell JD, Pacilio LE, Lindsay EK, Brown KW. Brief mindfulness meditation training alters psychological and neuroendocrine responses to social evaluative stress. Psychoneuroendocrinology. 2014 Jun;44:1–12.
  69. Yuan XL, Wang CY. Sleep deprivation-induced cognitive impairment: Unraveling the role of neuroinflammation. Experimental Neurology. 2025 Dec;394:115419.
  70. Younas A, Sarath Vayolipoyil, Shaheera Raghib, Bano S, Abali Wandala, Khan AA, et al. The Impact of Sleep Deprivation on Brain Fog, Cognitive Decline, and Cardiovascular Risk in Young Adults. Cureus. 2025 May 8;
  71. Zhu B, Dong Y, Xu Z, Gompf HS, Ward SAP, Xue Z, et al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiology of Disease [Internet]. 2012 Dec 1 [cited 2020 Oct 6];48(3):348–55. Available from: https://www.sciencedirect.com/science/article/pii/S0969996112002379?via%3Dihub
  72. Promsote W, Chumpolkulwong K, Musich T, Corley MJ, Ndhlovu LC, Sopanaporn J, et al. Impact of sleep deprivation on neurocognition and inflammation in rhesus macaques. Brain, Behavior, & Immunity – Health [Internet]. 2023 Nov 1;33:100683. Available from: https://www.sciencedirect.com/science/article/pii/S2666354623000972
  73. You Y, Li J, Zhang Y, Li X, Li X, Ma X. Exploring the potential relationship between short sleep risks and cognitive function from the perspective of inflammatory biomarkers and cellular pathways: Insights from population‐based and mice studies. CNS Neuroscience & Therapeutics. 2024 May 1;30(5).
  74. Obisesan TO. Hypertension and Cognitive Function. Clinics in Geriatric Medicine. 2009 May;25(2):259–88.
  75. Pacholko A, Costantino Iadecola. Hypertension, Neurodegeneration, and Cognitive Decline. Hypertension. 2024 Mar 1;81(5).
  76. Santisteban MM, Iadecola C, Carnevale D. Hypertension, Neurovascular Dysfunction, and Cognitive Impairment. Hypertension. 2022 Sep 21;80(1).
  77. Kang H, Ihara ES, Tompkins CJ, Lauber MS. Boosting Cognitive Training through Social Engagement: Impacts on Older Adults With Subjective Cognitive Decline. PubMed [Internet]. 2025 Aug 1;11. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12398649/?utm_source=chatgpt.com
  78. Liu Y, Lu G, Liu L, He Y, Gong W. Cognitive reserve over the life course and risk of dementia: a systematic review and meta-analysis. Frontiers in aging neuroscience. 2024 Apr 12;16
  79. SOCIAL ENGAGEMENT AND COGNITION WHAT IS ALREADY KNOWN [Internet]. Available from: https://www.alz.org/getmedia/a21fb0e8-f81b-4cf9-bc88-b2190b29f3a1/ph-bold-center-science-summary-social-engagement.pdf
  80. Millar CL, Iloputaife I, Baldyga K, Norling AM, Boulougoura A, Vichos T, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease. eBioMedicine. 2025 Mar;113:105612.
  81. Lee S, Wang EY, Steinberg AB, Walton CC, Chinta SJ, Andersen JK. A guide to senolytic intervention in neurodegenerative disease. Mechanisms of Ageing and Development [Internet]. 2021 Dec 1;200:111585. Available from: https://www.sciencedirect.com/science/article/pii/S0047637421001573#bib0260
  82. Ogrodnik M, Evans SA, Fielder E, Victorelli S, Kruger P, Salmonowicz H, et al. Whole‐body senescent cell clearance alleviates age‐related brain inflammation and cognitive impairment in mice. Aging Cell. 2021 Jan 20;20(2).
  83. Rani A, Bean L, Budamagunta V, Kumar A, Foster TC. Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging. Frontiers in Aging Neuroscience. 2024 May 15;16.
  84. Foster TC, Kumar A. Sex, senescence, senolytics, and cognition. Frontiers in Aging Neuroscience. 2025 Mar 4;17.
  85. Orr ME, Kotkowski E, Ramirez P, Bair-Kelps D, Liu Q, Brenner C, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience [Internet]. 2023 Nov 23; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828186/
  86. Thiyagarajan R, Muthaiah R, Sreevelu B, Treanor OP, Redae Y, Berman R, et al. Nicotinamide riboside supplementation restores microglial health and improves cognition in aged male mice. GeroScience [Internet]. 2025 Summer;10.1007/s11357-02501959-1. Available from: https://pubmed.ncbi.nlm.nih.gov/41273482/
  87. Kumar A, Bhagavathi Sundaram Sivamaruthi, Dey S, Kumar Y, Rishabha Malviya, Prajapati BG, et al. Probiotics as modulators of gut-brain axis for cognitive development. Frontiers in pharmacology. 2024 Feb 20;15.
  88. Kezer G, Spiros Paramithiotis, Khaoula Khwaldia, Iskandar Azmy Harahap, Čagalj M, Šimat V, et al. A comprehensive overview of the effects of probiotics, prebiotics and synbiotics on the gut-brain axis. Frontiers in Microbiology [Internet]. 2025 Oct 17;16:1651965–5. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12575349/
  89. Scribano P, Palau FG, Rodríguez SV, Rincon M, José M, Rodriguez MG, et al. Preclinical cognitive markers of Alzheimer’s disease and early diagnosis using virtual reality and artificial intelligence: a literature review. (Preprint). JMIR Medical Informatics. 2024 Jun 4;

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading